245 related articles for article (PubMed ID: 31958300)
1. Adherence to lipid-lowering therapy and risk for cardiovascular disease and death in type 1 diabetes mellitus: a population-based study from the Swedish National Diabetes Register.
Hero C; Karlsson SA; Franzén S; Svensson AM; Miftaraj M; Gudbjörnsdottir S; Andersson Sundell K; Eliasson B; Eeg-Olofsson K
BMJ Open Diabetes Res Care; 2020 Jan; 8(1):. PubMed ID: 31958300
[TBL] [Abstract][Full Text] [Related]
2. Refill adherence and persistence to lipid-lowering medicines in patients with type 2 diabetes: A nation-wide register-based study.
Karlsson SA; Hero C; Eliasson B; Franzén S; Svensson AM; Miftaraj M; Gudbjörnsdottir S; Eeg-Olofsson K; Andersson Sundell K
Pharmacoepidemiol Drug Saf; 2017 Oct; 26(10):1220-1232. PubMed ID: 28799214
[TBL] [Abstract][Full Text] [Related]
3. Association between refill adherence to lipid-lowering medications and the risk of cardiovascular disease and mortality in Swedish patients with type 2 diabetes mellitus: a nationwide cohort study.
Karlsson SA; Hero C; Svensson AM; Franzén S; Miftaraj M; Gudbjörnsdottir S; Eeg-Olofsson K; Eliasson B; Andersson Sundell K
BMJ Open; 2018 Mar; 8(3):e020309. PubMed ID: 29602853
[TBL] [Abstract][Full Text] [Related]
4. Impact of Socioeconomic Factors and Gender on Refill Adherence and Persistence to Lipid-Lowering Therapy in Type 1 Diabetes.
Hero C; Karlsson SA; Franzén S; Svensson AM; Miftaraj M; Gudbjörnsdottír S; Andersson-Sundell K; Eliasson B; Eeg-Olofsson K
Diabetes Ther; 2021 Sep; 12(9):2371-2386. PubMed ID: 34292559
[TBL] [Abstract][Full Text] [Related]
5. Association Between Use of Lipid-Lowering Therapy and Cardiovascular Diseases and Death in Individuals With Type 1 Diabetes.
Hero C; Rawshani A; Svensson AM; Franzén S; Eliasson B; Eeg-Olofsson K; Gudbjörnsdottir S
Diabetes Care; 2016 Jun; 39(6):996-1003. PubMed ID: 27208327
[TBL] [Abstract][Full Text] [Related]
6. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.
Elam MB; Ginsberg HN; Lovato LC; Corson M; Largay J; Leiter LA; Lopez C; O'Connor PJ; Sweeney ME; Weiss D; Friedewald WT; Buse JB; Gerstein HC; Probstfield J; Grimm R; Ismail-Beigi F; Goff DC; Fleg JL; Rosenberg Y; Byington RP;
JAMA Cardiol; 2017 Apr; 2(4):370-380. PubMed ID: 28030716
[TBL] [Abstract][Full Text] [Related]
7. Prescription of lipid-lowering medications for patients with type 2 diabetes mellitus and risk-associated LDL cholesterol: a nationwide study of guideline adherence from the Swedish National Diabetes Register.
Karlsson SA; Franzén S; Svensson AM; Miftaraj M; Eliasson B; Andersson Sundell K
BMC Health Serv Res; 2018 Nov; 18(1):900. PubMed ID: 30486824
[TBL] [Abstract][Full Text] [Related]
8. Patterns and predictors of medication adherence to lipid-lowering therapy in children aged 8 to 20 years.
Joyce NR; Wellenius GA; Eaton CB; Trivedi AN; Zachariah JP
J Clin Lipidol; 2016; 10(4):824-832.e2. PubMed ID: 27578113
[TBL] [Abstract][Full Text] [Related]
9. Lipid-lowering treatment patterns in patients with new cardiovascular events - estimates from population-based register data in Sweden.
Hallberg S; Banefelt J; Fox KM; Mesterton J; Johansson G; Levin LÅ; Sobocki P; Gandra SR
Int J Clin Pract; 2016 Mar; 70(3):222-8. PubMed ID: 26799539
[TBL] [Abstract][Full Text] [Related]
10. Risk of cardiovascular event and mortality in relation to refill and guideline adherence to lipid-lowering medications among patients with type 2 diabetes mellitus in Sweden.
Karlsson SA; Eliasson B; Franzén S; Miftaraj M; Svensson AM; Andersson Sundell K
BMJ Open Diabetes Res Care; 2019; 7(1):e000639. PubMed ID: 31114701
[TBL] [Abstract][Full Text] [Related]
11. Association between Dietary Intake and Lipid-Lowering Therapy: Prospective Analysis of Data from Australian Diabetes, Obesity, and Lifestyle Study (AusDiab) Using a Quantile Regression Approach.
Gadowski AM; Nanayakkara N; Heritier S; Magliano DJ; Shaw JE; Curtis AJ; Zoungas S; Owen AJ
Nutrients; 2019 Aug; 11(8):. PubMed ID: 31405073
[TBL] [Abstract][Full Text] [Related]
12. Single Pill Regimen Leads to Better Adherence and Clinical Outcome in Daily Practice in Patients Suffering from Hypertension and/or Dyslipidemia: Results of a Meta-Analysis.
Weisser B; Predel HG; Gillessen A; Hacke C; Vor dem Esche J; Rippin G; Noetel A; Randerath O
High Blood Press Cardiovasc Prev; 2020 Apr; 27(2):157-164. PubMed ID: 32219670
[TBL] [Abstract][Full Text] [Related]
13. More- Versus Less-Intensive Lipid-Lowering Therapy.
Toyota T; Morimoto T; Yamashita Y; Shiomi H; Kato T; Makiyama T; Nakagawa Y; Saito N; Shizuta S; Ono K; Kimura T
Circ Cardiovasc Qual Outcomes; 2019 Aug; 12(8):e005460. PubMed ID: 31412729
[TBL] [Abstract][Full Text] [Related]
14. Lipid-lowering drug adherence and combination therapy effects on gastrointestinal cancer in patients with dyslipidemia without diabetes: a retrospective cohort study in South Korea.
Han KT; Kim S
BMC Cancer; 2022 Feb; 22(1):156. PubMed ID: 35135497
[TBL] [Abstract][Full Text] [Related]
15. Association of a Combined Measure of Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and/or Ezetimibe.
Khunti K; Danese MD; Kutikova L; Catterick D; Sorio-Vilela F; Gleeson M; Kondapally Seshasai SR; Brownrigg J; Ray KK
JAMA Netw Open; 2018 Dec; 1(8):e185554. PubMed ID: 30646277
[TBL] [Abstract][Full Text] [Related]
16. The Management of Dyslipidaemia in Patients with Type 2 Diabetes Mellitus Receiving Lipid-Lowering Drugs: A Sub-Analysis of the CEPHEUS Findings.
Shehab A; Al-Rasadi K; Arafah M; Al-Hinai AT; Al Mahmeed W; Bhagavathula AS; Al Tamimi O; Al Herz S; Al Anazi F; Al Nemer K; Metwally O; Alkhadra A; Fakhry M; Elghetany H; Medani AR; Yusufali AH; Al Jassim O; Al Hallaq O; Baslaib FOAS; Alawadhi M; Amin H; Al-Hashmi K; Oulhaj A
Curr Vasc Pharmacol; 2018; 16(4):368-375. PubMed ID: 28677510
[TBL] [Abstract][Full Text] [Related]
17. Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus.
Berkelmans GFN; Gudbjörnsdottir S; Visseren FLJ; Wild SH; Franzen S; Chalmers J; Davis BR; Poulter NR; Spijkerman AM; Woodward M; Pressel SL; Gupta AK; van der Schouw YT; Svensson AM; van der Graaf Y; Read SH; Eliasson B; Dorresteijn JAN
Eur Heart J; 2019 Sep; 40(34):2899-2906. PubMed ID: 30629157
[TBL] [Abstract][Full Text] [Related]
18. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Keech A; Simes RJ; Barter P; Best J; Scott R; Taskinen MR; Forder P; Pillai A; Davis T; Glasziou P; Drury P; Kesäniemi YA; Sullivan D; Hunt D; Colman P; d'Emden M; Whiting M; Ehnholm C; Laakso M;
Lancet; 2005 Nov; 366(9500):1849-61. PubMed ID: 16310551
[TBL] [Abstract][Full Text] [Related]
19. Effects of lipid-lowering treatment intensity and adherence on cardiovascular outcomes in patients with a recent myocardial infarction: a Swedish register-based study.
Svensson MK; Sorio Vilela F; Leósdóttir M; Banefelt J; Lindh M; Dun AR; Norhammar A; Villa G
Ups J Med Sci; 2022; 127():. PubMed ID: 35722183
[TBL] [Abstract][Full Text] [Related]
20. Predicted impact of lipid lowering therapy on cardiovascular and economic outcomes of Swedish atherosclerotic cardiovascular disease guideline.
Journath G; Hambraeus K; Hagström E; Pettersson B; Löthgren M
BMC Cardiovasc Disord; 2017 Aug; 17(1):224. PubMed ID: 28814290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
